Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
This article was originally published in The Pink Sheet Daily
Executive Summary
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.